DIAGNOS will start a clinical trial study in the USA commencing December 6th, 2021 for early detection and prevention of Stroke using CARA-STROKE.
Diagnos Inc. (“DIAGNOS
” or the
”) (TSX Venture: ADK) (OTCQB: DGNOF), a
leader in early detection of critical health issues, announces
today the beginning of a clinical trial study with CommonSpirit
Health Research Institute, Chattanooga Center for Neurologic
Research LLC and conducted at the CommonSpirit Hospital in
Chattanooga, to confirm early Proof-of-Concept results that showed
a strong potential in the early detection of stroke through the
inspection and analysis of the retina, as mentioned in its press
release dated 2021-07-20.
The clinical trial will be carried out under the
direction of Thomas G Devlin M.D., PhD. The IRB study has been
approved by an Institutional Review Board (“IRB”) in compliance
with all applicable regulations in the USA.
DIAGNOS will be starting the clinical trial the
week of December 6th, DIAGNOS will be seeking to demonstrate that
CARA-ST (CARA STROKE) will be able to predict the early signs of
the condition leading to a stroke, based on the micro circulation
analysis of the retina image of the patient.
As per CDC-The Center for Disease Control and
Prevention, stroke causes 1 out of every 20 deaths, the management
of stroke represents a cost of around USD 34
billion per year in the United States. Hence, early
diagnosis and treatment to prevent deaths from stroke is a time
According to the World Health Organization, 15
million people suffer a stroke
worldwide each year. Of these, 5 million die and
another 5 million are permanently disabled. High blood pressure
contributes to more than 85% of strokes
worldwide. Europe averages
approximately 650,000 stroke related
deaths each year.
“According to new reports published by Worldwide
Research Institutes, the worldwide market size for Stroke
Management will hit over $66 Billion dollars by 2023. DIAGNOS
intends to be part of the solution by making available an
affordable predictive test to the general public,’’ said
Mr. André Larente, President of DIAGNOS.
“This year our new stroke management application
will be field tested in multiple countries. For our investors this
ground-breaking test comes at an ideal time in terms of shareholder
value creation as the combination of both CARA-DR and CARA-ST tools
will be transformational in helping to monitor the health of
existing and future patients with cardiovascular disease,” said Mr.
Andre Larente, President of DIAGNOS.
Health is a non for profit, Catholic health system dedicated to
advancing health for all people. It was created in February 2019
through the alignment of Catholic Health initiatives and Dignity
Health. With a team of approximately 125,000 physicians and
advanced practice clinicians. CommonSpirit Health operates 137
hospitals and more than 1,000 care sites across 21 states. In
FY2020, Catholic Health initiatives and Dignity Health had combined
revenues of nearly $29.6 billion and provided $4.6 billion in
charity care, community benefit and unreimbursed government
About DIAGNOSDIAGNOS is a
publicly traded Canadian corporation dedicated to early detection
of critical health problems based on its FLAIRE Artificial
Intelligence (AI) platform. FLAIRE allows for quick modifying and
developing of applications such as CARA (Computer Assisted Retina
Analysis). CARA’s image enhancement algorithms provide sharper,
clearer and easier-to-analyze retinal images. CARA is a
cost-effective tool for real-time screening of large volumes of
patients. CARA has been cleared for commercialization by the
following regulators: Health Canada, the FDA (USA), CE (Europe),
COFEPRIS (Mexico) and Saudi FDA (Saudi Arabia).
Additional information is available at
www.diagnos.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
Tel: 450-678-8882 ext. 224
IR Pro Communications Inc.
Dir: +1 604-507-3377
Historical Stock Chart
From Dec 2021 to Jan 2022
Historical Stock Chart
From Jan 2021 to Jan 2022